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Amyotrophic Lateral Sclerosis (ALS) is a fatal motoneuron disease that is characterized
by the degradation of neurons throughout the central nervous system. Inflammation have
been cited a key contributor to ALS neurodegeneration, but the timeline of cytokine
upregulation remains unresolved. The goal of this study was to temporally examine
the correlation between the varying levels of pro-inflammatory type I cytokines (IL-1β,
IL-1α, IL-12, TNF-α, and GFAP) and anti-inflammatory type II cytokines (IL-4, IL-6, IL-10)
throughout the progression of ALS in the SOD1 G93A mouse model. Cytokine level
data from high copy SOD1 G93A transgenic mice was collected from 66 peer-reviewed
studies. For each corresponding experimental time point, the ratio of transgenic to wild
type (TG/WT) cytokine was calculated. One-way ANOVA and t-tests with Bonferonni
correction were used to analyze the data. Meta-analysis was performed for four discrete
stages: early, pre-onset, post-onset, and end stage. A significant increase in TG cytokine
levels was found when compared to WT cytokine levels across the entire SOD1 G93A
lifespan for majority of the cytokines. The rates of change of the individual cytokines,
and type I and type II were not significantly different; however, the mean fold change of
type I was expressed at significantly higher levels than type II levels across all stages with
the difference between the means becoming more pronounced at the end stage. An
overexpression of cytokines occurred both before and after the onset of ALS symptoms.
The trend between pro-inflammatory type I and type II cytokine mean levels indicate
a progressive instability of the dynamic balance between pro- and anti-inflammatory
cytokines as anti-inflammatory cytokines fail to mediate the pronounced increase in
pro-inflammatory cytokines. Very early immunoregulatory treatment is necessary to
successfully interrupt ALS-induced neuroinflammation.
Keywords: amyotrophic lateral sclerosis, inflammation, cytokine, interleukin, GFAP, TNF-α, G93A, SOD1
INTRODUCTION
Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disease that is characterized
by the rapid degradation of motor neurons over the course of the disease, resulting in
paralysis, respiratory failure, and ultimately death. ALS is multi-faceted pathophysiology,
which includes axonal transport deficiency; upregulation of apoptotic cascades; changes
Abbreviations: ALS, Amyotrophic Lateral Sclerosis; SOD1, superoxide dismutase gene; TG, transgenic; GFAP, Glial fibrillary
acidic protein; TNF-α, Tumor necrosis factor alpha; IL, Interleukin.
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in cellular chemistry, including metallation and enzymes;
cellular energetics deficiencies; excitability, including changes
in neurotransmitters and transporters; inflammation, including
increased microglia activation and gliosis; oxidative stress,
including increases in free intracellular oxidants and anti-
oxidants; protein deregulation, including increased protein
aggregates and decreased autophagy; and systemic contributors,
including those of muscular and non-neuromuscular origin
(Irvin et al., 2015; Kim et al., 2015). For a recent in-
depth informatics-based review of the entire SOD1 G93A
field, including an overview of the nine previously mentioned
pathophysiological categories, please see (Kim et al., 2015).
Inflammation, or more specifically neuroinflammation, is
one of the more heavily researched ALS contributors (Kim
et al., 2015), which is frequently assessed in the familial
or transgenic superoxide dismutase-1 guanine 93 to alanine
(SOD1 G93A) murine model (Pfohl et al., 2015). Although
the crucial role of neuroinflammation in the pathology of ALS
is evident, the extent to which the inflammatory response is
neurotoxic, and the balance of the inflammatory regulation
and deregulation over the course of the disease progression
remain unclear (McCombe and Henderson, 2011; Evans et al.,
2013).
Currently, the drug Riluzole has shown to be slightly effective
in extending patient survival by 75 days through targeting
inflammation caused by glutamate (Riviere et al., 1998; McGeer
and McGeer, 2002). Other inflammatory treatments have also
shown to significantly increase life expectancy. The inflammatory
enzyme COX-2 has been found in high levels in G93A mice
(Almer et al., 2001), and in vivo trials in mice using COX-2
inhibitors have yielded great results, extending life expectancy
by upwards of 20% (Drachman et al., 2002). Possible treatments
reducing pathological inflammation regulation may be used in
conjunction to achieve a greater impact in the treatment of ALS
(McGeer and McGeer, 2002).
Cytokines, the primary messenger molecules of the
inflammatory response, are released from leukocytes, microglia,
and astrocytes (Hart, 2003). In a non-pathological state, cytokines
use complex signaling cascades in order to yield a balanced and
non-toxic, protective immune response to the target site
(Greenhalgh and Hilton, 2001). Type I cytokines increase
the inflammatory response (i.e., type I = pro-inflammatory),
while type II cytokines decrease the inflammatory response
(i.e., type II = anti-inflammatory; Dong et al., 2011). However,
pathological overexpression of cytokines or disturbance of their
intricate balance can cause the overall inflammatory response
to be damaging rather than protective (Papadimitriou et al.,
2010). Possible primary inducers of ALS inflammation include
glutamate excitotoxicity and oxidative stress due to free radical
accumulation (Mitchell and Lee, 2012; Kim et al., 2015). Primary
and secondary activation of microglia and astrocytes further
exacerbates the release of pro-inflammatory cytokines and
nitric oxide through a positive feedback loop (Mitchell and Lee,
2008).
Upregulation of pro-inflammatory cytokines is thought to
be associated with an increased severity of symptoms in ALS
(Nguyen et al., 2004). However, the exact timeline of cytokine
disturbance remains unclear (McCombe and Henderson, 2011).
In this study, we present a quantitative, comprehensive
examination of cytokines over the entire course of the SOD1
G93A transgenic mouse ALS disease progression. Moreover, we
assess the relationship between type I and type II cytokines as
a function of ALS progression. We hypothesized that type I
cytokine levels would increase significantly in comparison to type
II cytokine levels at each disease stage with this difference more
pronounced in the latter stages of the disease. Our meta-analysis
includes data from 66 peer-reviewed experimental studies, which
measured cytokine levels in both transgenic G93A SOD1 mice
(TG) and in wild type mice (WT). The fold changes, with
respect to WT levels, of cytokines are compared across the
lifespan of the SOD1G93A TGmouse, using four discrete disease
stages—early, pre-symptom onset, post-symptom onset, and end
stage.
METHODS
Literature Search
To obtain the initial primary article selection pool, PubMed
searches were conducted in October 2014 to find all published
articles with (“Amyotrophic Lateral Sclerosis” OR “ALS”) in the
title or abstract AND (“transgenic mouse” OR “G93A”) in the title
or abstract (Kim et al., 2015; Pfohl et al., 2015). Initial primary
article selection pool exclusion criteria consisted of: non-English
language articles; articles for which full-text pdf downloads were
unavailable; and articles labeled as literature reviews. Articles
were either downloaded using PubMed Central or from e-journal
subscriptions available from the libraries of Georgia Institute of
Technology and Emory University.
Information from the articles was entered systematically
into a relational database using the software FileMaker Pro
13 Advanced (Filemaker, Inc.; Kim et al., 2015) and included
stringent quality control procedures (Mitchell et al., 2015a).
Aggregate data pertaining to cytokine levels of TG mice was
mined using a predetermined list of cytokines (Table 1), which
included alternate spellings [e.g., IL-1α, interleukin 1a, IL-1a, IL-
alpha, IL-1(alpha), etc.]. Searches were performed in the article
title, abstract, figure captions, and within figure text to find
relevant articles from the primary article pool (Kim et al., 2015;
Pfohl et al., 2015). These searches resulted in a study selection
pool of 153 articles from which initial data was collected. The
following list of inclusion and exclusion criteria was used to
extract data, shown in Table 2, relevant to cytokine level.
Study Inclusion Criteria
• Cytokines and small proteins that were directly related with
cytokine effects. Table 1 provides a brief outline of the
cytokines measured in this study (Ferguson-Smith et al., 1988;
Kriegler et al., 1988; Hsieh et al., 1993; Eskdale et al., 1997;
Suzuki et al., 2003; Ribotta et al., 2004; Von Boyen et al., 2004;
Sokol et al., 2008; Dinarello, 2011; Pedersen, 2013). Although
glial fibrillary acid protein (GFAP) is not a cytokine, it was
categorized with type I cytokines, since GFAP levels correlates
directly with an increase in the activity of pro-inflammatory
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TABLE 1 | Cytokine outline.
Cytokine Type Background description
IL-1α I IL-1α and IL-1ß are the interleukins most directly associated with acute and chronic inflammation, and they share the same receptor and
coreceptor IL-1RI and IL-1RacP, respectively (Dinarello, 2011).IL-1β I
IL-12 I IL-12 is known as a type I T cell stimulating factor, which can stimulate the growth and function of T cells, including tumor necrosis factor alpha
(TNFα) (Hsieh et al., 1993). IL-12 P70 heterodimer promotes the differentiation of type I helper cells which produce more type I cytokines. IL-12
P40 homodimer is an antagonist that is generally present when levels of IL-12 P70 heterodimer are in excess (Suzuki et al., 2003).
TNF-α I TNFα is a type I cytokine released from M1 macrophages and is involved in triggering apoptosis (Kriegler et al., 1988).
GFAP I Glial fibrillary acidic protein (GFAP) has been shown to be upregulated in autoimmune diseases where TNFα and IL-1ßwere overexpressed (Von
Boyen et al., 2004), causing glial scarring as the astrocytes interact with neural injuries (Ribotta et al., 2004).
IL-4 II IL-4 is the interleukin primarily responsible for the differentiation of helper T cells to Th2 cells that participate in the anti-inflammatory response
(Sokol et al., 2008).
IL-6 II IL-6 was originally defined as a pro-inflammatory cytokine secreted by T cells and macrophages (Ferguson-Smith et al., 1988). However, IL-6
has more recently been shown to have anti-inflammatory properties when released by muscle cells (Pedersen, 2013).
IL-10 II IL-10 is an anti-inflammatory cytokine commonly known as human cytokine synthesis inhibitory factor (CSIF) (Eskdale et al., 1997).
These cytokines were included in this study due to their high prevalence in the primary article pool.
cytokines, and GFAP increases with damage to the central
nervous system (Ribotta et al., 2004)
• Measures dealing with densities, mRNA or protein levels, and
fold change for each of the cytokines
• High transgene copy SOD1 G93A murine model (TG) B6SJL-
Tg.
Study Exclusion Criteria
• Data that did not measure cytokine counts or expressions
either directly or indirectly
• Measures with treatment on the mouse model
• Data in which there was no evident manner to normalize the
results
• Purely in vitro data
• Cytokine levels measured greater than 136 days (see Section
Data Normalization).
Data Normalization
In order to account for the variation of cytokine level
measurement methods between the many papers, cytokine level
data were normalized by the calculation of ratios of TG to
WT cytokine levels. In the case that a TG value did not have
a WT value for corresponding time point, if at least one WT
timepoint was present, that one WT value was used to normalize
the TG value as the WT value was observed to be constant
with age (Ringer et al., 2009). Each ratio was then weighted
according to the sample size found for its respective study. When
sample size values were not explicitly or clearly reported in
papers (Kang et al., 2003; Weydt et al., 2004; Xie et al., 2004;
Kiaei et al., 2006; Kassa et al., 2009; Finkelstein et al., 2011;
Audet et al., 2012; Dibaj et al., 2012), a value of 1 was used for
the sample size in the statistical analysis in order to allow for
the data to make a conservative, yet deserved, impact on the
analysis.
Disease Stages
The disease stages were determined by taking the mean and
standard deviation of all reported time of onset (97 ± 20), and
of all reported time of death (135 ± 19) in the papers included,
andmarking one standard deviation before and after these means
as critical points for the ranges. The resultant four defined time
periods are as follows: 0–76 days (early stage), 77–96 days (pre-
onset stage), 97–116 day (post-onset stage), 117–135 days (end
stage). Data after themean time of death (135 days) was excluded,
since data was only available for two type I cytokines, TNF-α or
GFAP.
Analysis
A right tailed t-test was used to test the statistical significance
of the means of each cytokine level against the null hypothesis
that the cytokine levels between TG and WT was unchanged for
each time period or disease stage. Shapiro-Wilk test was used to
determine that the TG/WT ratio data was normally distributed.
To insure a conservative assessment, Bonferroni correction was
used to lower the defined statistical significance to p < 0.002.
One-way ANOVA was used to test the significance of means
for each defined time period. ANCOVA was used to test the
significance of the rate of change of cytokine levels among
the different cytokines, and among grouped type I and type II
cytokines, for each defined time period; the significance level for
this comparison was set as α = 0.05. MATLAB (The Mathworks,
Inc.) was used to perform the statistical analysis. A meta-analysis
with fixed effects was also conducted using metan in Stata
(Statacorp, 2015). Since meta-analysis is more conservative in
terms of data inclusion criteria, meta-analysis for the studies with
type I cytokines was done. While the forest plots look at studies
compared to each other, the meta-analysis using normalized data
operates under a similar fixed effects model in which the value of
each study, instead of the study itself, is weighted using sample
size.
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TABLE 2 | Summary of data.
Cytokine Total papers Total ratios References
IL-4 6 7 Hensley et al., 2002, 2003; Kim et al., 2006; Beers et al., 2008; Chiu et al., 2008; Audet et al., 2012
IL-6 8 12 Hensley et al., 2002, 2003; Weydt et al., 2004; Xie et al., 2004; Kim et al., 2006; Chiu et al., 2008; Audet et al., 2012;
Dibaj et al., 2012
IL-10 3 6 Hensley et al., 2002, 2003; Finkelstein et al., 2011
IL-1α 5 6 Hensley et al., 2003; Kiaei et al., 2006; Kim et al., 2006; Kassa et al., 2009; Neymotin et al., 2009
IL-1β 12 20 Hensley et al., 2003; Kang et al., 2003; Xie et al., 2004; Kiaei et al., 2006; Kim et al., 2006; Kassa et al., 2009;
Neymotin et al., 2009; Fang et al., 2010; Zhao et al., 2010; Berger et al., 2011; Audet et al., 2012; Valente et al., 2012
IL-12 6 12 Hensley et al., 2002, 2003, 2006; Kiaei et al., 2006; Kim et al., 2006; Dibaj et al., 2012
TNF-α 18 39 Yoshihara et al., 2002; Hensley et al., 2003; Chen et al., 2004; Weydt et al., 2004; Xie et al., 2004; Perrin et al., 2005;
Henkel et al., 2006; Kim et al., 2006; Zhang et al., 2008; Cheroni et al., 2009; Neymotin et al., 2009; Fang et al., 2010;
Takeuchi et al., 2010; Finkelstein et al., 2011; Pollari et al., 2011; Audet et al., 2012; Valente et al., 2012
GFAP 46 164 Olsen et al., 2001; Yoshihara et al., 2002; Liu and Martin, 2006; Ohta et al., 2006; Pardo et al., 2006; Guan et al.,
2007; Petrik et al., 2007; Yin et al., 2007; Beers et al., 2008; Pitzer et al., 2008; Poesen et al., 2008; Shibata et al.,
2008; Boucherie et al., 2009; Cheroni et al., 2009; Kassa et al., 2009; Keller et al., 2009, 2011; Ringer et al., 2009;
Sekiya et al., 2009; Yang et al., 2009, 2011; Guo et al., 2010, 2011; Israelsson et al., 2010; Jokic et al., 2010;
Moreno-Igoa et al., 2010; Shimazawa et al., 2010; Steinacker et al., 2010; Suzuki et al., 2010; Tsai et al., 2010; Berger
et al., 2011; Finkelstein et al., 2011; Genestine et al., 2011; Zhu and Sheng, 2011; Gifondorwa et al., 2012; Miquel
et al., 2012; Valente et al., 2012
Type I total 56 241 Olsen et al., 2001; Hensley et al., 2002, 2003, 2006; Yoshihara et al., 2002; Kang et al., 2003; Chen et al., 2004;
Weydt et al., 2004; Xie et al., 2004; Perrin et al., 2005; Henkel et al., 2006; Kiaei et al., 2006; Kim et al., 2006; Liu and
Martin, 2006; Ohta et al., 2006; Pardo et al., 2006; Guan et al., 2007; Petrik et al., 2007; Yin et al., 2007; Beers et al.,
2008; Pitzer et al., 2008; Poesen et al., 2008; Shibata et al., 2008; Zhang et al., 2008; Boucherie et al., 2009; Cheroni
et al., 2009; Kassa et al., 2009; Keller et al., 2009, 2011; Neymotin et al., 2009; Ringer et al., 2009; Sekiya et al., 2009;
Yang et al., 2009, 2011; Fang et al., 2010; Guo et al., 2010, 2011; Israelsson et al., 2010; Jokic et al., 2010;
Moreno-Igoa et al., 2010; Shimazawa et al., 2010; Steinacker et al., 2010; Suzuki et al., 2010; Takeuchi et al., 2010;
Tsai et al., 2010; Zhao et al., 2010; Berger et al., 2011; Finkelstein et al., 2011; Genestine et al., 2011; Pollari et al.,
2011; Audet et al., 2012; Dibaj et al., 2012; Gifondorwa et al., 2012; Miquel et al., 2012; Valente et al., 2012
Type II total 10 25 Hensley et al., 2002, 2003; Weydt et al., 2004; Xie et al., 2004; Kim et al., 2006; Beers et al., 2008; Chiu et al., 2008;
Finkelstein et al., 2011; Audet et al., 2012; Dibaj et al., 2012
Information gathered on each cytokine that was suitable for use in the statistical analysis.
RESULTS
Experimental in vivo data on cytokines levels in transgenic (TG)
SOD1 G93A ALS mice and wild type (WT) mice was utilized
from a total of 66 peer-reviewed articles, which met the study
inclusion criteria. The ratio of TG to WT cytokine levels at each
examined time point was calculated, resulting in total of 266
TG/WT ratios. TG/WT cytokine level ratio is plotted for each
specific cytokine type over the TG mouse life span (Figure 1).
Figure 2A illustrates the data included in our meta-analysis,
separated by disease stage. Individual cytokines are aggregated
and presented by their corresponding type, type I (Figure 2B)
or II (Figure 2C). Since pro-inflammatory type I cytokines are
generally viewed as having a larger role in the progression of ALS,
type II (IL-4, IL-6, and IL-12) cytokines have been less studied
in the experimental literature; consequently, there is less type II
cytokine data.
Differences in TG Levels Compared to WT
Levels in and Across Each Stage
In Figure 3, the means of the fold change for all cytokines within
each time period is positive with the exception of themeans of IL-
6 and TNF-α. At the early stage, the fold changes of IL-6 (0.7214)
and TNF-α (0.9369) appear to be qualitatively less than WT, but
are not statistically significant. The fold changes of all the other
cytokines are greater than one, indicating that the TG cytokine
levels were overexpressed relative to WT cytokine levels.
Among the individual type I cytokines, IL-1α, IL-1ß, and
GFAP show significance in their fold increase (p < 0.0001) across
all of the four stages. TNF-α shows significance in fold increase
in all stages except for pre-onset, and IL-12 does not show any
significance at stages where sufficient data was present to be
tested. Across aggregated type I cytokines, increase of TG levels
relative to WT levels is statistically significant for each disease
stage (Figure 4).
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FIGURE 1 | Normalized cytokine levels used to assess differences between SOD1 G93A transgenic mice (TG) and wild type (WT) mice over time or
post-natal age (days). Plot of individual cytokine levels, (A) IL-1α, (B) IL-1ß, (C) IL-4, (D) IL-6, (E) IL-10, (F) TNF-α (G) GFAP, and (H) IL-12, used in the analysis.
Of type II cytokines, IL-6, and IL-10 show significance in
increase in all stages where sufficient data were present (Figure 3,
marked with ∗). In contrast, IL-4 showed statistically insignificant
increases in both the early and end disease stages (Figure 3).
Across the four stages for type I cytokines, the GFAP level
expression increased significantly across all stages (Figure 3,
marked with+). TNF-α expression increased significantly across
the first three stages. IL-β levels are increased in the early,
post-onset and end stages, but not for pre-onset. IL-1α, IL-
12, IL-4, IL-6, and IL-10 contain missing data in crucial
stages to reach conclusive results. Overall, the rate of type
I cytokine levels increased significantly across the first three
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FIGURE 2 | Normalized cytokine levels over time separated by the four
stages utilized for statistical analysis, early (0–76 days), pre-onset
(77–96 days), post-onset (97–116 days), and end stages (117–135
stages). (A). Plot of all raw data cytokine ratios (TG/WT) for type I and type II
cytokines. (B). Cytokines ratios (TG/WT) for type I cytokines only. (C). Cytokine
ratios (TG/WT) for type II cytokines only.
stages (Figure 4, marked with +). Type II cytokines expression
increased significantly across the first three stages (Figure 4,
marked with +), but decreased significantly from the post-onset
stage to the end stage (Figure 4, marked with –).
Fold Change Difference Between Type I
and Type II Cytokines
In Figure 4, the mean fold increase of type I is not only greater
than that of type II across all four stages, but the difference
was also statistically significant in all four stages. The difference
between the means increases from early to pre-onset stage. At the
post-onset stage, the difference does not continue this increase,
but, instead, decreases slightly as a result of the increase in
anti-inflammatory response to mediate the overexpression of
the inflammatory response. Toward the end stage, the inability
of the pathological system to compensate for the increase in
FIGURE 3 | Means of normalized cytokine levels (TG/WT) for each of
the four SOD1 G93A ALS mouse disease stages: early, pre-onset,
post-onset, and end. Statistically significant differences between SOD1
G93A transgenic mice (TG) and wild type (WT) levels within a disease stage
are marked with asterisk (*). Statistically significant positive or negative fold
changes across consecutive disease stages are represented by plus (+) or
minus (−), respectfully. Significance was adjusted to p < 0.002 using
Bonferroni correction. Error bars represent confidence interval.
FIGURE 4 | Means of normalized type I and type II for each of the four
SOD1 G93A ALS mouse disease stages: early, pre-onset, post-onset,
and end stage. Type I cytokines were significantly higher than type II
cytokines for each of the four stages. Statistically significant differences
between SOD1 G93A transgenic mice (TG) and wild type (WT) levels within a
disease stage are marked with asterisk (*). Statistically significant positive or
negative fold changes across consecutive stages are represented by plus (+)
or minus (–), respectfully. Significance was adjusted to p < 0.006 using
Bonferroni correction. Error bars represent confidence intervals.
pro-inflammatory response to maintain dynamic stability is seen
through the abrupt increase in the difference of the fold changes.
Meta-Analysis of Type I Cytokines
Due to the type of data and the experimental heterogeneity
of the assessed measures and each study’s precision, standard
meta-analysis as a stand-alone method does not provide
sufficient dynamical assessment (Higgins et al., 2003), in terms
of examining both cytokine rate changes and fold changes.
Nonetheless, it is valuable for assessing the contributions of
individual studies and providing very conservative affirmation
of the quantified significance of fold change in cytokines. From
the meta-analysis, there is no statistical significance in the results
between each of the studies in the early and post-onset stages, but
there is statistical significance in that of pre-onset and end stages
as shown in the results from the forest plot (see Supplementary
Table 1). Therefore, the conservative results of the meta-analysis
are supportive of the results described above using traditional
statistics with Bonferroni correction. Finally, the I2 statistics for
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each of these stages with the exception of pre-onset stage indicate
that, as would be expected, there is considerable heterogeneity
between studies.
Differences in Rate of Change of Fold
Changes Between Individual Cytokines,
and Between Type I and Type II Cytokines
In Table 3, for each of the four time periods, both the rate of
change of each cytokine compared to the average rate of change,
and the rate of change of each type compared to the average rate
of change in each stage were not significant.
DISCUSSION
While end stage cytokine levels have been described in
various studies on the TG model, our analysis especially
sheds light on the previously underrepresented early stage and
pre-onset cytokine levels (McCombe and Henderson, 2011).
Overexpression of individual cytokines was expected near
end stage. However, interestingly, overexpression of individual
cytokines also occurred in the early and pre-onset stages, well
before the measurable appearance of physical symptoms. GFAP,
a clear indicator of inflammation, is expressed twice the WT
cytokine levels in the early stage, well before the onset of
the disease, and the protein continues to significantly increase
throughout disease progression, reaching almost 4.5 times the
WT counterpart (Siemionow et al., 2009).
In addition to the expected increase in pro-inflammatory type
I cytokine levels in stages after onset, type I cytokine levels
in TG mice also increased relative to WT mice significantly
before the onset of the disease. This early deviation from the
normal aggregate type I cytokine levels reveals the start of
the inflammatory response well before the symptomatic stage.
Overall, as a group, type II cytokines show significantly different
means only in the pre-onset and post-onset stages (Figure 4,
marked with ∗). Unfortunately, there is a general lack of data to
draw strong conclusions regarding expression of individual type
II cytokines.
Aggregating the individual cytokines respective to their types
yields a more holistic view of the pro- and anti-inflammatory
balance in ALS. Type II cytokine level rates increase appropriately
across the first three stages to counteract the overexpression of
type I cytokines. However, at the end stage, type II cytokines
fail to maintain this appropriate response, thereby facilitating
the increased effect of pro-inflammatory response on neuronal
damage. This disruption in immunoregulatory balance is a
remnant of the overall regulatory instability that is a contributor
to ALS (Irvin et al., 2015).
In response to the disruption in the balance between pro and
anti-inflammatory responses via the increase in type I cytokine
levels, type II cytokine levels should also increase to mediate
this imbalance (Philips and Robberecht, 2011). However, type
II exhibits the opposite of the appropriate response. Although
both types of cytokines increase significantly over the first three
stages of the disease, type I cytokine levels plateau at the end
stage, but type II cytokine levels decrease significantly (Figure 4).
The insignificant change in type I cytokine levels in the end
stage may have an impact on the decrease in expression of type
II cytokine levels. Interestingly, after onset, the immune system
appears to balance the rates of change of the cytokines as the
disease progresses, although the mean cytokine levels remain
elevated.
Despite the pathological state, which causes TGmice cytokine
levels to be generally overexpressed, the rates at which the
cytokines change across time for each stage do not indicate
an aberrant cytokine. Rather, the increase or decrease of each
cytokines aligns with the average change of cytokine levels in the
TABLE 3 | Rate of change of type I vs. type II cytokine levels at each stage.
Cytokine Early stage Pre-onset stage Post-onset stage End stage
Slope p-value Slope p-value Slope p-value Slope p-value
IL-4 0.0525 – – – 0.114 – 0.048 0.7967
IL-6 0.086 0.678 – – 0.183 0.8791 0.079 0.7575
IL-10 – – −0.022 – 0.114 – 0.055 0.8923
IL-1α 0.1467 0.694 – – 0.114 – −0.293 0.4438
IL-1ß 0.023 0.6311 −0.022 – 0.322 0.4816 −0.193 0.5885
IL-12 0.0525 – −0.022 – 0.114 – 0.060 0.7262
TNF-α −0.001 0.3854 −0.193 0 −0.018 0.6047 −0.197 0.4126
GFAP 0.0079 0.4669 0.149 0 −0.031 0.4595 0.229 0.0404
Average 0.0525 0.3918 −0.022 0.4771 0.114 0.5279 −0.034 0.759
Type I 0.0104 0.1837 0.0658 – −0.0227 0.8224 0.242 0.356
Type II 0.0964 0.1837 – – 0.0655 0.8224 0.05 0.356
Average 0.0534 0.0991 – – 0.0214 0.9134 0.146 0.1619
The p-value for the average slope shows the significance of slope differing from zero. None of the rates of change of cytokines or types of cytokines are significantly different from their
respective average slopes.
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system. This could indicate that the mechanisms which causes
changes of cytokine levels over the disease progression occurs
as a result of a system response against inflammation caused by
the ALS pathology, such as gliosis, and not as a direct cause of
the ALS pathology, itself. This is similar to recent hypotheses
suggestion that the hallmark amyloid beta plaques in Alzheimer’s
disease could be a side effect rather than the direct cause of
cognitive decline (Foley et al., 2015). The lower prevalence of
antecedent disease in clinical ALS population (Mitchell et al.,
2015b) indicates that inflammation is likely a side effect, rather
than a precursor, of ALS.
The results of our study suggest that inflammation may have
more of a crucial role in the earlier stages of ALS. Although
gliosis through the perturbation of microglia and astrocytes
by cytokine molecules act as protective barriers for normal
injuries, unregulated, continued increase of pro-inflammatory
cytokine levels in a pathological state can cause unnecessary
gliosis that cause damage and is harmful (Papadimitriou et al.,
2010). As a result, immunoregulatory treatments to decrease
inflammation by increasing the anti-inflammatory response may
be more effective when administered earlier in the course of
ALS. Such treatments administered later in the disease may
have little, if any, impact since the pro-inflammatory cytokines
have already reached the crucial levels. Interestingly, similar
observations have been made in regards to timing the treatment
of neuroinflammation in secondary spinal cord injury (Mitchell
and Lee, 2008).
The traditional school of thought has been to utilize type I
cytokine inhibitors or type II cytokine activators to limit the
high levels of inflammation. For example, a historical study
that used COX-2 inhibitors as treatments showed significant
decrease in inflammatory responses (McGeer andMcGeer, 2002).
However, the results of the present study reveal that the ability
to actually modulate the immunoregulatory response, and do so
with precise timing, may bemore favorable. In fact, recent studies
attempting immunoregulatory modulation have shown promise.
For example, immunizations with a myelin-derived antigen have
been utilized to stimulate immunoregulatory cell recruitment,
ultimately attenuating disease progression in the ALS mouse
model (Kunis et al., 2015). Other strategies have included
immunomodulatory effects of humanmesenchymal stem cells on
peripheral blood mononuclear cells in ALS patients (Kwon et al.,
2014), altering the native environment of neuroprotective T-cells
(Mesnard-Hoaglin et al., 2014), and the usage of IgG antibodies
as biomarkers (Schwartz and Baruch, 2014).
Perhaps the most exciting therapeutic hypothesis to date is
to boost native autoimmunity. Autoimmune T-cells are part
of a cellular network which, to operate efficiently and safely,
requires tight regulation by other immune cell populations,
such as regulatory T cells, which are indispensable for
maintenance of immunological self-tolerance and homeostasis
(Schwartz and Baruch, 2014). It has been previously suggested
that dysregulation of the balance between peripheral immune
suppression, on one hand, and protective autoimmunity, on
the other, is an underlying mechanism in the emergence and
progression of the neuroinflammatory response associated with
chronic neurodegenerative diseases and brain aging (Schwartz
and Baruch, 2014). The dynamical instability between type I
and II cytokines in SOD1 G93A ALS mice, as identified in
the present study, is supportive of the immune dysregulation
hypothesis. The ability to exploit the intricate relationships and
immunoregulatory pathways via cellular therapy is an exciting
path for the future of ALS treatment (Rizzo et al., 2014).
Finally, the testing of anti-inflammatory treatments in
various time ranges, and not simple presence or absence of
anti-inflammatory treatment, may achieve not only a deeper
understanding of the possible mechanisms of the balance
between pro- and anti-inflammatory responses, but also give
rise to a more effective treatment that may further extend life
expectancy.
CONCLUSIONS
It is evident that the levels of most of the individual cytokines
in TG are generally higher than their corresponding WT
counterpart for all four disease stages. Pro-inflammatory type I
cytokines are expressed at higher levels than anti-inflammatory
type II cytokines across all stages. Moreover, type I cytokine levels
increase significantly across the first three stages, whereas type
II cytokine levels increase significantly until the post-onset stage
and then decrease at the end stage. The pronounced increase
in difference between inflammatory and anti-inflammatory
throughout the life span of ALS mice is likely due to the inability
of the pathological system tomaintain stability (Mitchell and Lee,
2012). In fact, type I normalized TG levels are∼four times greater
than WT in the post-onset and end stages, whereas the type II
normalized TG levels are only two times greater for the post-
onset stage and almost equivalent toWT levels at end stage. Early
intervention and immunoregulatory modulation addressing the
dynamic neuroinflammatory instability are two keys to future
treatment success. Finally, assessment of homeostatic regulation
failure in inflammation and other cellular pathways remains a
promising avenue for identifying the underlying etiology of ALS
(Irvin et al., 2015).
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